RVAC Medicines
MRNA platform company engaged in the research and development of innovative products such as vaccines for diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
€509—764m (Dealroom.co estimates Apr 2022.)
Singapore (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
* | $140m | Series B | |
Total Funding | €127m |